Short answer
ZEVRA THERAPEUTICS, INC. (ZVRA) filed its Q3 2025 10-Q quarterly report on Nov 5, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $26M (up 605.4% year over year) with net income of −$544,000.
Q3 2025 key financials · XBRL
- Revenue
- $26M
- +605.4% YoY · +0.7% QoQ
- Net income
- −$544,000
- +98.4% YoY · −100.7% QoQ
- Operating margin
- 15.9%
- EPS (diluted)
- $0.00
- +100.0% YoY · −100.0% QoQ
Source: XBRL data from the ZEVRA THERAPEUTICS, INC. (ZVRA) Q3 2025 10-Q on SEC EDGAR. USD.
ZEVRA THERAPEUTICS, INC. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- OLPRUVA impairment charge $58.7 million for nine months ended September 30, 2025
- MIPLYFFA enrollment 137 patients as of September 30, 2025
- PRV sale generated net proceeds of $148.3 million on April 1, 2025
- European MIPLYFFA MAA submitted July 2025; EMA decision pending
Risk Factors
- New tariffs and retaliatory trade measures, triggered by recent U.S. actions, could increase commercialization and development costs
- $58.7 million intangible-asset impairment charge recognized for the quarter ended June 30, 2025
- July 2025 One Big Beautiful Bill Act Medicaid funding cuts could reduce coverage and sales of MIPLYFFA® and OLPRUVA®
- $100,000 H-1B payment requirement announced September 19, 2025 could raise recruitment costs for international personnel
- Medicaid, 340B, VA/FSS and Tricare reporting errors could trigger refunds, civil penalties, sanctions or False Claims Act exposure
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ZEVRA THERAPEUTICS, INC. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.